title: Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication.
abstract: BACKGROUND
  Chronic myeloid leukemia (CML), is the first malignancy that related to the chromosomal abnormality and include 15-20% of all adulthood leukemia.
  
  
  OBJECTIVE
  This study aimed to compare the hematologic, breakpoint cluster region-abelson (BCR-ABL) and liver function enzymes changes during treatment period of Imatinib.
  
  
  METHODS
  A noncurrent clinical trial study.
  
  
  METHODS
  New incident CML patients received Iranian made or Indian-made Imatinib after baseline measurement. Hematologic, BCR-ABL, electrolytes and liver function enzymes measured again after 24 weeks.
  
  
  METHODS
  Paired t-test and independent t-test was used to assess the effect of treatment in within and between groups, respectively.
  
  
  RESULTS
  Imatinib has a decreasing impact on white blood cells and placates. While an increasing effect on hemoglobin concentration. Iranian made and Indian-made Imatinib has a same effect on improvement of hematologic, BCR-ABL, electrolytes in CML patients. However, the liver changes of Imatinib were not clinically significant.
  
  
  CONCLUSIONS
  The Iranian-made Imatinib can be used as a replacement for Indian made ones without any statistical and clinical significant difference on Improvement of CML patients.
authors.forename: K
authors.initials: K
authors.lastname: Moshfeghi
authors.forename: N
authors.initials: N
authors.lastname: Nazemizadeh
authors.forename: V
authors.initials: V
authors.lastname: Mehrzad
authors.forename: A
authors.initials: A
authors.lastname: Hajiannejad
authors.forename: F
authors.initials: F
authors.lastname: Esmaeili
authors.affiliation: Department of Epidemiology and Biostatistics, Health Policy and Promotion Research Center, Qom University of Medical Sciences, Qom, Iran.
authors.forename: A
authors.initials: A
authors.lastname: Mohammadbeigi
mesh_terms: D000368:Aged; D001772:Blood Cell Count; D002869:Chromosome Aberrations; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004573:Electrolytes / Q000097:blood; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000097:blood / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage* / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged
chemical_list: D004573:Electrolytes; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl